Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Bone Density Loss: The Most Alarming Long-Term Risk Here's the data that should make every woman on GLP-1 medications pay attention: A 2024 randomized controlled trial found that 52 weeks of semaglutide reduced hip bone density by 2.6% and lumbar spine density by 2.1% compared to placebo The FDA issued a warning for Wegovy, noting increased hip and pelvis fractures in female patients : 1% on Wegovy vs
[1] [2] These studies suggest that visceral fat may decrease proportionally during GLP-1-induced weight loss, similar to patterns seen with dietary caloric restriction
The main trial programs are STEP for Wegovy (semaglutide) and SURMOUNT for Zepbound (tirzepatide)
1 If youve just found out youre pregnant and youve been taking Wegovy, its recommended to stop the medication and contact your prescriber, GP, or midwife
US$ 28.61
US$ 25.37
US$ 24.38
US$ 22.05
US$ 21.32
US$ 27.47
